DrugId:  1
1. Name:  Dienestrol
2. Groups:  Approved, Investigational
3. Description:  Dienestrol is a synthetic, non-steroidal estrogen. It is an estrogen receptor agonist. Estrogens work partly by increasing a normal clear discharge from the vagina and making the vulva and urethra healthy. Using or applying an estrogen relieves or lessens: dryness and soreness in the vagina, itching, redness, or soreness of the vulva. Conditions that are treated with vaginal estrogens include a genital skin condition (vulvar atrophy), inflammation of the vagina (atrophic vaginitis), and inflammation of the urethra (atrophic urethritis).
4. Indication:  For use in the treatment of atrophic vaginitis and kraurosis vulvae.
DrugId:  2
1. Name:  QAV-680
2. Groups:  Investigational
3. Description:  QAV680 has been used in trials studying the treatment of Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis.
4. Indication:  Not Available
DrugId:  3
1. Name:  CAT-213
2. Groups:  Investigational
3. Description:  CAT-213 is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development. It is developed by MedImmune for the treatment of Allergic Rhinitis.
4. Indication:  Investigated for use/treatment in allergic rhinitis.
DrugId:  4
1. Name:  SB-705498
2. Groups:  Investigational
3. Description:  SB-705498 has been investigated for the treatment of Rhinitis, Chronic Cough, and Non-allergic Rhinitis.
4. Indication:  Not Available
DrugId:  5
1. Name:  GSK-1004723
2. Groups:  Investigational
3. Description:  Gsk1004723 has been investigated for the treatment of Allergic Rhinitis and Rhinitis, Allergic, Seasonal.
4. Indication:  Not Available
DrugId:  6
1. Name:  JNJ-39220675
2. Groups:  Investigational
3. Description:  JNJ-39220675 has been used in trials studying the treatment of Allergic Rhinitis.
4. Indication:  Not Available
DrugId:  7
1. Name:  Tranilast
2. Groups:  Approved, Investigational
3. Description:  Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
4. Indication:  For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
DrugId:  8
1. Name:  Propylhexedrine
2. Groups:  Approved
3. Description:  Propylhexedrine is an alpha-adrenergic agonist often used in nasal decongestant inhalers. It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.
4. Indication:  It is used to provide temporary symptomatic relief of nasal congestion due to colds, allergies and allergic rhinitis.
DrugId:  9
1. Name:  GSK-256066
2. Groups:  Investigational
3. Description:  Gsk256066 has been used in trials studying the treatment and diagnostic of SAR, Asthma, Mild Asthma, Allergic Rhinitis, and Seasonal Allergic Rhinitis, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  Rupatadine
2. Groups:  Approved
3. Description:  Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing in Canada under the tradename Rupall and comes in tablet formulation for adult use and liquid formulation for pediatric use.
4. Indication:  For the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older [FDA Label]. Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older.
DrugId:  11
1. Name:  Estrone
2. Groups:  Approved
3. Description:  Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
4. Indication:  For management of perimenopausal and postmenopausal symptoms.
DrugId:  12
1. Name:  HT-0712
2. Groups:  Investigational
3. Description:  BLX-028914 has been used in trials studying the treatment and basic science of Allergic Rhinitis and Age-Associated Memory Impairment (AAMI).
4. Indication:  Not Available
DrugId:  13
1. Name:  Tecastemizole
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in allergic rhinitis.
DrugId:  14
1. Name:  PDE4
2. Groups:  Investigational
3. Description:  Merck has developed a selective PDE4 inhibitor for the treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease. Whereas the potential therapeutic utility of PDE4 inhibition has been demonstrated in various preclinical animal models (e.g., in rheumatoid arthritis and multiple sclerosis), clinical evaluation has been restricted by dose-limiting side effects, mainly nausea and emesis.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  15
1. Name:  Fevipiprant
2. Groups:  Investigational
3. Description:  Fevipiprant has been used in trials studying the treatment of Asthma, Atopic Dermatitis, and Allergic Rhinitis.
4. Indication:  Not Available
DrugId:  16
1. Name:  REV131
2. Groups:  Investigational
3. Description:  rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
4. Indication:  Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts.
DrugId:  17
1. Name:  Levocabastine
2. Groups:  Approved, Investigational
3. Description:  Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
4. Indication:  As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray for allergic rhinitis.
DrugId:  18
1. Name:  Danazol
2. Groups:  Approved
3. Description:  A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. [PubChem]
4. Indication:  For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
DrugId:  19
1. Name:  Pentagastrin
2. Groups:  Approved
3. Description:  A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid. [PubChem]
4. Indication:  Used as a diagnostic aid for evaluation of gastric acid secretory function
DrugId:  20
1. Name:  Thonzylamine
2. Groups:  Approved
3. Description:  Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with Clofedanol or Phenylephrine for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.
4. Indication:  Not Available
DrugId:  21
1. Name:  Azelastine
2. Groups:  Approved
3. Description:  Azelastine, a phthalazine derivative, is an antihistamine and mast cell stabilizer available as a nasal spray for hay fever and as eye drops for allergic conjunctivitis. Azelastine is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patient over 12 years old for symptomatic relief of seasonal allergic rhinitis.
4. Indication:  For the symptomatic treatment of seasonal allergic rhinitis and non-allergic rhinitis, as well as symptomatic relief of ocular itching associated with allergic conjunctivitis.
DrugId:  22
1. Name:  Triprolidine
2. Groups:  Approved
3. Description:  First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness.
4. Indication:  For the symptomatic relief of seasonal or perennial allergic rhinitis or nonallergic rhinitis; allergic conjunctivitis; and mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Also used in combination with other agents for the symptomatic relief of symptoms associated with the common cold.
DrugId:  23
1. Name:  Chloropyramine
2. Groups:  Approved
3. Description:  Chloropyramine is a first generation antihistamine drug approved in some Eastern European countries for the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions. Related indications for clinical use include Quincke's edema, allergic reactions to insect bites, food and drug allergies, and anaphylactic shock.
4. Indication:  For the treatment of allergic conjunctivitis, allergic rhinitis, bronchial asthma, and other atopic (allergic) conditions.
DrugId:  24
1. Name:  Ketotifen
2. Groups:  Approved
3. Description:  A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
4. Indication:  Indicated as an add-on or prophylactic oral medication in the chronic treatment of mild atopic asthmatic children. Also used as self-medication for the temporary relief of itching of the eye due to allergic conjunctivitis (ophthalmic).
DrugId:  25
1. Name:  Beclomethasone dipropionate
2. Groups:  Approved, Investigational
3. Description:  Beclomethasone dipropionate is a prodrug of the free form, beclomethasone (beclomethasone-17-monopropionate). An anti-inflammatory, synthetic corticosteroid, it is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma and allergic rhinitis (seasonal and perennial). Beclometasone dipropionate is also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease. It is marketed under several brand names such as Qnasl (US) and Rivanase AQ (Canada).
4. Indication:  Used in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older, and in treating symptoms for allergic rhinitis (seasonal or perennial) in patients 12 years of age and older. Also being investigated for oral treatment in mild-to-moderate Crohn's disease of ileal or ileal-right colonic localisation and for "topical" use mild-to-moderate graft versus host disease.
